Aug 17: The Union Cabinet, chaired by Prime Minister Shri Narendra Modi, was apprised of a Memorandum of Understanding (MoU) signed on 4th June 2023 between the Indian Pharmacopoeia Commission (IPC), Ministry of Health & Family Welfare, Government of the Republic of India and Ministry of Health, Government of the Republic of Suriname for Recognition of Indian Pharmacopoeia (IP) in Suriname. This was signed during the visit of the President of India to Suriname.
The parties recognize the importance of developing close cooperation and exchanging information in the field of the regulation of medicines in accordance with their respective laws and regulations and reach the following understandings:
- to accept Indian Pharmacopoeia (IP) as a book of standards for medicines in Suriname so as to ensure the quality of medicines being manufactured and/or imported in Suriname;
- to accept the Certificate of Analysis issued by Indian manufacturers per IP and to do away with the requirement of duplicate testing of the medicines in Suriname;
- to get IPRS and Impurity standards from IPC at a reasonably low cost to be used during the quality control analysis;
- to have better scope for the development of generic medicines and contribute to availability of affordable medicines in Suriname;
- to promote an understanding of pharmacopoeia in the regulatory framework, requirements and processes;
- to facilitate the exchange of information and documentation relating to the development of monographs of IP;
- to enhance the ability of regulatory authorities in the provision of their services relating to or in connection with public health, to meet the needs of their respective population;
- to explore opportunities for technical cooperation in areas of mutual benefit in the development of monographs and future technologies.
The Memorandum of Understanding will facilitate the export of medical products leading to foreign exchange earnings. This would be a step towards an Atmanirbhar Bharat.
International recognition of the Indian pharmacopoeia! Standards have several benefits for the Indian pharmaceutical sector. These include:
- It would boost the export of Indian pharmaceutical products to these countries as it would remove double regulation, duplication in testing and post-importation checks. Indian drug exporters would thus, gain a competitive edge and trade would become more remunerative.
- Further, importing nations would gain access to quality Indian medical products at affordable prices.
- Manufacturers in importing countries would have better scope for
the development of generic medicines contributing to the availability of affordable
medicines to their citizens. - The various reference standards and impurity standards would become available to these manufacturers at a reasonable cost.
Convergence in the regulatory practices could help in increasing the export of medicines from India and consequentially help in better employment opportunities for educated professionals in the Pharmaceutical sector.
The Indian Pharmacopoeia (IP) is officially recognized by five (5) countries: Afghanistan, Ghana, Nepal, Mauritius and the Republic of Suriname. The Ministry seeks to expand the nations which recognize the IP.
Disclaimer: We donot claim that the images used as part of the news published are always owned by us. From time to time, we use images sourced as part of news or any related images or representations. Kindly take a look at our image usage policy on how we select the image that are used as part of the news.
